These studies also contributed toward defining the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter as one of the most relevant prognostic markers in GBM patients [7,8,9,10,11]. The gene discussed is MGMT; the disease is glioblastoma.